Act Healthy: A Randomized Clinical Trial Evaluating a Behavioral Activation Intervention to Address Substance Use and Medication Adherence Among Low-Income, Black/African American Individuals Living with HIV/AIDS

Baptiste-Roberts K, Hossain M. Socioeconomic disparities and self-reported substance abuse-related problems. Addict Health. 2018;10(2):112–22. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8. Díaz RM, Ayala G, Bein E, Henne J, Marin BV. The impact of homophobia, poverty, and racism on the mental health of gay and bisexual Latino men: findings from 3 US cities. Am J Public Health. 2001;91(6):927–32. English D, Rendina HJ, Parsons JT. The effects of intersecting stigma: A longitudinal examination of minority stress, mental health, and substance use among Black, Latino, and multiracial gay and bisexual men. Psychol Violence. 2018;8(6):669–79. McCabe SE, Bostwick WB, Hughes TL, West BT, Boyd CJ. The relationship between discrimination and substance use disorders among lesbian, gay, and bisexual adults in the United States. Am J Public Health. 2010;100(10):1946–52. McKirnan DJ, Vanable PA, Ostrow DG, Hope B. Expectancies of sexual “escape” and sexual risk among drug and alcohol-involved gay and bisexual men. J Subst Abuse. 2001;13(1–2):137–54. Turner WL, Wallace B. African American substance use: Epidemiology, prevention, and treatment. Violence Women. 2003;9(5):576–89. Vilsaint CL, NeMoyer A, Fillbrunn M, Sadikova E, Kessler RC, Sampson NA, et al. Racial/ethnic differences in 12-month prevalence and persistence of mood, anxiety, and substance use disorders: Variation by nativity and socioeconomic status. Compr Psychiatry. 2019;89:52–60. Alegría M, Alvarez K, Ishikawa RZ, DiMarzio K, McPeck S. Removing obstacles to eliminating racial and ethnic disparities in behavioral health care. Health Aff (Millwood). 2016;35(6):991–9. Health Resources and Services Administration, Office of Health Equity. Health Equity Report 2017 [Internet]. Rockville, Maryland: U.S.: Department of Health and Human Services; 2018. Available from: https://www.hrsa.gov/sites/default/files/hrsa/health-equity/2017-HRSA-health-equity-report.pdf Magidson JF, Li X, Mimiaga MJ, Moore AT, Srithanaviboonchai K, Friedman RK, et al. Antiretroviral medication adherence and amplified HIV transmission risk among sexually active HIV-infected individuals in three diverse international settings. AIDS Behav. 2016;20(4):699–709. Khazanchi R, Sayles H, Bares SH, Swindells S, Marcelin JR. Neighborhood deprivation and racial/ethnic disparities in human immunodeficiency virus viral suppression: a single-center, cross-sectional study in the United States midwest. Clin Infect Dis. 2020;72(10):642–5. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5. Daughters SB, Magidson JF, Anand D, Seitz-Brown CJ, Chen Y, Baker S. The effect of a behavioral activation treatment for substance use on post-treatment abstinence: a randomized controlled trial: Behavioral activation for substance use. Addiction. 2018;113(3):535–44. Magidson JF, Gorka SM, MacPherson L, Hopko DR, Blanco C, Lejuez CW, et al. Examining the effect of the life enhancement treatment for substance use (LETS ACT) on residential substance abuse treatment retention. Addict Behav. 2011;36(6):615–23. Martínez-Vispo C, Martínez Ú, López-Durán A, Fernández del Río E, Becoña E. Effects of behavioural activation on substance use and depression: a systematic review. Subst Abuse Treat Prev Policy [Internet]. 2018 Dec [cited 2019 Dec 22];13(1). Available from: https://substanceabusepolicy.biomedcentral.com/articles/https://doi.org/10.1186/s13011-018-0173-2 Mimiaga MJ, Reisner SL, Pantalone DW, O’Cleirigh C, Mayer KH, Safren SA. A pilot trial of integrated behavioral activation and sexual risk reduction counseling for HIV-uninfected men who have sex with men abusing crystal methamphetamine. AIDS Patient Care Stds. 2012;26(11):681–93. Daughters SB, Magidson JF, Lejuez CW, Chen Y. LETS ACT: a behavioral activation treatment for substance use and depression Jaime Delgadillo and Dr Frances Kay D, editor. Adv Dual Diagn. 2016;9(2/3):74–84. Daughters SB, Braun AR, Sargeant MN, Reynolds EK, Hopko DR, Blanco C, et al. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with elevated depressive symptoms: the life enhancement treatment for substance use (LETS Act!). J Clin Psychiatry. 2008;69(1):122–9. Mimiaga MJ, Pantalone DW, Biello KB, Hughto JMW, Frank J, O’Cleirigh C, et al. An initial randomized controlled trial of behavioral activation for treatment of concurrent crystal methamphetamine dependence and sexual risk for HIV acquisition among men who have sex with men. AIDS Care. 2019;31(9):1083–95. Chen Y, Anand D, Li H, Xu P, Daughters SB. Feasibility, acceptability and future adaptation of the Chinese translated behavioural activation treatment for depression: a pilot study. Int J Psychol. 2021;56(2):238–48. Collado A, Calderón M, MacPherson L, Lejuez C. The efficacy of behavioral activation treatment among depressed Spanish-speaking Latinos. J Consult Clin Psychol. 2016;84(7):651–7. Belus JM, Rose AL, Andersen LS, Ciya N, Joska JA, Myers B, et al. Adapting a behavioral intervention for alcohol use and HIV medication adherence for lay counselor delivery in Cape Town, South Africa: A case series. Cogn Behav Pract. 2020;1:1077722920301103. Magidson JF, Joska JA, Myers B, Belus JM, Regenauer KS, Andersen LS, et al. Project Khanya: a randomized, hybrid effectiveness-implementation trial of a peer-delivered behavioral intervention for ART adherence and substance use in Cape Town, South Africa. Implement Sci Commun. 2020;1(1):23. Patel V, Weobong B, Nadkarni A, Weiss HA, Anand A, Naik S, et al. The effectiveness and cost-effectiveness of lay counsellor-delivered psychological treatments for harmful and dependent drinking and moderate to severe depression in primary care in India: PREMIUM study protocol for randomized controlled trials. Trials [Internet]. 2014 Dec [cited 2019 Dec 9];15(1). Available from: https://trialsjournal.biomedcentral.com/articles/https://doi.org/10.1186/1745-6215-15-101 Patel V, Weobong B, Weiss HA, Anand A, Bhat B, Katti B, et al. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. The Lancet. 2017;389(10065):176–85. Daughters SB, Magidson JF, Schuster RM, Safren SA. ACT HEALTHY: A combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users. Cogn Behav Pract. 2010;17(3):309–21. Safren SA, Otto MW, Worth JL. Life-steps: Applying cognitive behavioral therapy to HIV medication adherence. Cogn Behav Pract. 1999;6(4):332–41. Kuo I, Greenberg AE, Magnus M, Phillips G, Rawls A, Peterson J, et al. High prevalence of substance use among heterosexuals living in communities with high rates of AIDS and poverty in Washington. DC Drug Alcohol Depend. 2011;117(2–3):139–44. Hill CE. Helping skills facilitating exploration, insight and action. 2nd ed. Washington, D.C.: American Psychological Association; 2004. Jastak SRichards, Wilkinson GS, Jastak Assessment systems. Wide range achievement test : WRAT-R. Rev. 1984. Los Angeles, Calif.: Western Psychological Services; 1984. First MB, Williams JBW, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). New York: Biometrics Research: New York State Psychiatric Institute; 2007. Sobell LC, Sobell MB. Timeline follow-back. Totowa, NJ: Humana Press; 1992. p. 41–72. Avants SK, Margolin A, DePhilippis D, Kosten TR. A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. J Subst Abuse Treat. 1998;15(3):261–5. McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (Modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: A pilot study. Am J Drug Alcohol Abuse. 2009;35(1):34–7. Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners Speck RF, editor. PLoS ONE. 2012;7(5):38335. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: The impact of buprenorphine treatment. J Urban Health. 2010;87(4):592–602. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care. 2000;12(3):255–66. DiIorio C, McCarty F, DePadilla L, Resnicow K, Holstad MM, Yeager K, et al. Adherence to antiretroviral medication regimens: A test of a psychosocial model. AIDS Behav. 2009;13(1):10–22. Magidson JF, Listhaus A, Seitz-Brown CJ, Safren SA, Lejuez CW, Daughters SB. Can behavioral theory inform the understanding of depression and medication nonadherence among HIV-positive substance users? J Behav Med. 2015;38(2):337–47. O’Cleirigh C, Ironson G, Smits JAJ. Does distress tolerance moderate the impact of major life events on psychosocial variables and behaviors important in the management of HIV? Behav Ther. 2007;38(3):314–23. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227–45. Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio TX Psychol Corp. 1996;1:82. Leon GD, Melnick G, Kressel D, Jainchill N. Circumstances, motivation, readiness, and suitability (the CMRS scales): Predicting retention in therapeutic community treatment. Am J Drug Alcohol Abuse 1994;20(4):495–515. Collins SE, Malone DK, Larimer ME. Motivation to change and treatment attendance as predictors of alcohol-use outcomes among project-based Housing First residents. Addict Behav. 2012;37(8):931–9. Myers B, van der Westhuizen C, Naledi T, Stein DJ, Sorsdahl K. Readiness to change is a predictor of reduced substance use involvement: Findings from a randomized controlled trial of patients attending South African emergency departments. BMC Psychiatry [Internet]. 2016 Dec [cited 2020 Apr 1];16(1). Available from: http://www.biomedcentral.com/1471-244X/16/35 Raudenbush SW, Bryk AS. Hierarchical linear models: applications and data analysis methods. 2nd ed. Thousand Oaks: Sage Publications; 2002. 485 p. (Advanced quantitative techniques in the social sciences). Chakraborty H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values [Internet]. Washington, DC: RTI Press; 2009 Apr [cited 2019 Dec 22]. Available from: http://www.rti.org/publication/mixed-model-approach-intent-treat-analysis-longitudinal-clinical-trials-missing-values Mallinckrodt C. Analyzing longitudinal clinical trial data: A practical guide [Internet]. 1st ed. Boca Raton : CRC Press, 2017. Chapman and Hall/CRC; 2016 [cited 2020 Oct 23]. Available from: https://www.taylorfrancis.com/books/9781315186634 SAS. Cary, NC: SAS Institute Inc.; 2018. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behavioral therapies research: Getting started and moving on from stage I. Clin Psychol Sci Pract. 2006;8(2):133–42. Decker KP, Peglow SL, Samples CR, Cunningham TD. Long-term outcomes after residential substance use treatment: Relapse, morbidity, and mortality. Mil Med. 2017;182(1):e1589–95. Greenwood GL, Woods WJ, Guydish J, Bein E. Relapse outcomes in a randomized trial of residential and day drug abuse treatment. J Subst Abuse Treat. 2001;20(1):15–23. Mooney SR, Horton PA, Trakowski JH, Lenard JH, Barron MR, Nave PV, et al. Military inpatient residential treatment of substance abuse disorders: the eisenhower army medical center experience. Mil Med. 2014;179(6):674–8. Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82–8. Maiti DPM, Das T, Ramasamy S, Xavier A, Behera AS, Selvarajan SK. An overview on medication-assisted treatment (MAT) for opioid dependence. J Opioid Manag. 2020;16(2):141–9. Rombouts SA, Conigrave JH, Saitz R, Louie E, Haber P, Morley KC. Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. BMC Fam Pract. 2020;21(1):260. Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety. Subst Abuse. 2016;37(2):286–98. Higgins ST, Wong CJ, Badger GJ, Ogden DEH, Dantona RL. Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol. 2000;68(1):64–72. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994;51(7):568–76. Strona FV, McCright J, Hjord H, Ahrens K, Tierney S, Shoptaw S, et al. The acceptability and feasibility of the positive reinforcement opportunity project, a community-based contingency management methamphetamine treatment program for gay and bisexual men in San Francisco. J Psychoactive Drugs. 2006;38(sup3):377–83. Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug Alcohol Depend. 2004;74(1):1–13. Denis-Lalonde D, Lind C, Estefan A. Beyond the buzzword: A concept analysis of harm reduction. Res Theory Nurs Pract. 2019;33(4):310–23. Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006;25(6):611–24. Williams DR, Collins C. Racial residential segregation: A fundamental cause of racial disparities in health. Public Health Rep. 2001;116(5):404–16. Meyer IH, Schwartz S, Frost DM. Social patterning of stress and coping: Does disadvantaged social statuses confer more stress and fewer coping resources? Soc Sci Med. 2008;67:368–79. Satinsky EN, Doran K, Felton JW, Kleinman M, Dean D, Magidson JF. Adapting a peer recovery coach-delivered behavioral activation intervention for problematic substance use in a medically underserved community in Baltimore City. PLoS ONE. 2020;15(1):0228084. Acuff SF, Dennhardt AA, Correia CJ, Murphy JG. Measurement of substance-free reinforcement in addiction: a systematic review. Clin Psychol Rev. 2019;70:79–90. Safren SA, Bedoya CA, O’Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. Lancet HIV. 2016;3(11):e529–38. Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable. JAMA. 2019;321(5):451. Frieden TR, Foti KE, Mermin J. Applying public health principles to the HIV epidemic — How are we doing? N Engl J Med. 2015;373(23):2281–7. Beck AT, Steer RA, Carbin MG. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100.